Truescope Acquires US Firm Universal Information Services ACN Newswire

Truescope Acquires US Firm Universal Information Services

February 1, 2023
SYDNEY, AU, Feb 1, 2023 - (ACN Newswire via SEAPRWire.com) - Australian media intelligence company, Truescope, has strengthened its position in North America by acquiring leading agency, Universal Information Services (UIS).Todd Murphy, Truescope President, North America & John Croll, Truescope Co-founder and CEOFounded in 2019 and now operating in Singapore, New Zealand, and North America, Truescope is experiencing rapid growth in all markets - a commercial response to the company's advanced SaaS platform, product innovation and experienced people. The acquisition of UIS will immediately welcome many hundreds of clients to the Truescope solution, with the integration of services presently underway.UIS is led by industry authority, Todd Murphy based in Omaha, Nebraska. The competitive media intelligence agency has a rich heritage and proud reputation for its service-first approach, and as a trusted partner to businesses and communication professionals across the United States. Truescope co-founder and CEO, John Croll, said the acquisition was a significant move to accelerate growth in the large US media intelligence market, which he believes has been underserved for some time and is ready to evolve through innovation."Truescope has been active in the US for almost a year and the response we have had to our platform has been overwhelmingly positive" he said. "Todd's leadership, the Universal team's decades long local expertise and loyal client base, coupled with Truescope's technology, will enable us to deliver a powerful and truly unparalleled service that will help better inform communications," said John.Following the departure of Meg Crumbine in late 2022, Todd Murphy will take on the role of Truescope President, North America, effective immediately, with his first strategic priority being to oversee the UIS integration.Todd is enthusiastic about the opportunities ahead for the new alliance saying, "John's vision and ability to build game-changing tech is the perfect alignment for the evolution of not only Universal's clients but the media intelligence industry, broadly. I'm thrilled to be leading the company and delivering a truly superior service never before seen," he said.Migration of UIS clients to the Truescope platform is currently underway, with the merger of the UIS brand and business to Truescope to take place over the coming months.For media information or to interview John Croll and/or Todd Murphy, contact:Shelley Hammond | shelley@oneroofagency.com.au | +61 427 547 898About TruescopeTruescope was founded in Australia to better inform communications. Our people and technology deliver real-time, actionable media intelligence and information to clients across Asia, New Zealand, and the United States. Visit www.truescope.com for more. Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech Acquires US-based Drug Development Consulting Firm, CBR International ACN Newswire

Novotech Acquires US-based Drug Development Consulting Firm, CBR International

January 12, 2023
SINGAPORE, Jan 12, 2023 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific-centered biotech CRO today announced the acquisition of CBR International, a global product development, clinical oversight and strategic regulatory operations group.CBR was founded in 2002 as a consultancy company focused on assisting biotechnology and pharma companies navigate FDA requirements from early-stage development through to approval. CBR adds a group of experts to Novotech to provide US and global regulatory, scientific, quality, and clinical development services. CBR's specific regulatory expertise and services include long-range Regulatory Strategy and Writing, FDA Representation, eSubmissions, and Scientific Affairs to support requirements for cGMP commercial product development.The acquisition will further strengthen Novotech's capabilities in regulatory strategy and US FDA interactions and submissions including IND, IDE, NDA, BLA, Fast-Track, Break-through, and Orphan Drug Applications.Novotech CEO Dr. John Moller said: "CBR will provide decades of FDA regulatory experience for our biotech clients. They have experience across all product types and are highly regarded for their IND expertise having managed approximately 80 INDs through all phases of development. This acquisition, together with Novotech's existing regulatory affairs capability, creates a large global group of experts in toxicology, drug development, and global regulatory submissions support. This regulatory expertise benefits our US, European, and Asia Pacific biotech clients as they progress through the US clinical environment and navigate often complex FDA requirements."CEO and Founder of CBR, Dr. Jeanne Novak said: "We are extremely pleased to be joining a company the size and calibre of Novotech which brings global demand for our regulatory expertise. The US is an important region for global biotech and pharma companies as part of their clinical program development. We have the experience and track-record of directly supporting US approvals for over 10 programs. Navigating novel product development and achieving multiple approvals has built our expertise to support the complex development needs of clients worldwide which will now support Novotech clients. We look forward to working with Novotech clients to support their drug development programs in the US and globally. We are excited to continue working with our clients and bringing Novotech expanded services to our colleagues."Novotech has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership and flexibility. Consistent investment in advanced training and technology combines to deliver a specialist full-service biotech CRO solution.Novotech has recently been recognised with significant CRO awards including the Asia-Pacific Biotech CRO of the Year by Frost & Sullivan, benchmarked as a top 10 CRO among the world's leading CROs, a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About NovotechNovotech is the leading Asia-Pacific centered biotech CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. Novotech is well-positioned to serve biotech clients conducting clinical trials in Asia-Pacific the US, and Europe. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech Acquires European CRO, Strengthens Global Operations ACN Newswire

Novotech Acquires European CRO, Strengthens Global Operations

January 12, 2023
SINGAPORE, Jan 12, 2023 - (ACN Newswire via SEAPRWire.com) - Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech's global expansion program. EastHORN was established in 2004 and has over 250 employees.The acquisition means biotech clients can access Novotech's unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.Novotech CEO Dr. John Moller said: "This acquisition is a strategic move to further expand our CRO operations and provide biotech clients with in-country expertise across Asia-Pacific, North America, and Europe to deliver their global drug development programs. EastHORN and Novotech have been working together for many years and we share a culture of clinical excellence in biotech drug development. EastHORN which is retaining its brand, is now a Novotech company and will be integrated into our systems and processes so clients benefit from working with one CRO globally. Clients can now access our exceptional European infrastructure, local knowledge, site relationships and access to diverse patient populations."EastHORN Executive Chairman Iain Gordon said: "I first started working on clinical projects with Novotech 15 years ago and have always been impressed by the quality of their services and their client-focused approach. EastHORN has been working closely with Novotech for over a decade now and have many friends within the Novotech team. This is a natural next step for our group and my colleagues and I are excited to become part of Novotech's global operations to support biotech clients' clinical programs. In particular, we can now offer our clients access to Novotech's team of experts across Asia-Pacific and the US including project management, regulatory, clinical, medical and biometrics, while our team's European expertise can advance clinical development in Europe for Novotech clients. We work with similar-sized biotechs and small to mid-size pharma companies and have experience across the same therapeutic areas, so this is an excellent cultural and strategic fit."Novotech has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership and flexibility. Consistent investment in advanced training and technology combines to deliver an exceptional full-service biotech CRO solution.Novotech has recently been recognised with significant CRO awards including the Asia-Pacific Biotech CRO of the Year by Frost & Sullivan, benchmarked as a top 10 CRO among the world's leading CROs, a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About Novotech Novotech is the leading Asia-Pacific centred biotech CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. Novotech is well-positioned to serve biotech clients conducting clinical trials in Asia-Pacific, the US, and Europe. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Avance Clinical Celebrates GlobalReady Success as more than 40 Biotech Clients Enter Program ACN Newswire

Avance Clinical Celebrates GlobalReady Success as more than 40 Biotech Clients Enter Program

January 11, 2023
SAN FRANCISCO, CA, Jan 11, 2023 - (ACN Newswire via SEAPRWire.com) - More than 40 biotech clients are now taking advantage of Avance Clinical's GlobalReady program which delivers streamlined clinical development from early phase in Australia expanding to sites in North America for later phases. All with the one CRO and dedicated teams across both regions.Avance Clinical made the announcement at Biotech Showcase 2023 where the team is taking meetings via PartnershipOne. "Given this successful early adoption of GlobalReady we are expecting more than half of our biotech clients to join the program within the next six months, said Avance Clinical CEO Yvonne Lungershausen.GlobalReady biotech clients are primarily biotechs from the US and Asia, with an increasing number expected from Europe over the next few months.Avance Clinical is the leading Australian-based biotech CRO with US operations, which has been recognized by Frost & Sullivan for the past 3 years with the prestigious CRO Leadership Award.CEO Yvonne Lungershausen said: "These biotech clients are already benefiting from our expansion into North America and GlobalReady. The GlobalReady model is designed to extend biotechs' investments so they can achieve greater clinical development milestones with reduced spend, all with the assurance of FDA-accepted data. GlobalReady gives our biotech clients conducting their early phase studies in Australia and New Zealand a seamless journey into the US to continue their clinical development programs, retaining the same high-quality CRO, which reduces time and cost and delivers quality FDA-accepted data. In addition, the attractive 43.5% rebate on clinical spend in Australia, offers our clients the opportunity to utilize our North American operations expertise and team, whilst maintaining services in Australia to maximize their rebate potential. We often point to the fact that there are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which again demonstrates Australian data acceptability with the FDA and other major regulatory authorities."This seamless GlobalReady journey is designed for success whereby biotechs can:- Take advantage of the Australian early-phase clinical trial landscape (No IND and 43.5% tax rebate)- Transition or expand into North America for later phases - without changing CROs (retain study knowledge and processes/team)- Seamlessly operationalize global dose-escalation and dose-expansion trials across the two regions- Harness significant speed and cost advantages- Be assured of quality data - transferable and readily acceptable by the FDA and other regulatory authorities"We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biotech clients need for clinical success," commented Yvonne Lungershausen.According to Frost & Sullivan as part of the independent analyst review of the company for the CRO Award: "Avance Clinical remains a trusted partner, earning a reputation for delivering the overall best in the CRO industry. With its strong overall performance, Avance Clinical earns Frost & Sullivan's 2022 Asia-Pacific Customer Value Leadership Award in the contract research organization industry."Find out more:- Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/- Learn about the GlobalReady model here https://www.avancecro.com/avance-clinical-north-america-operations/- For more information about the benefits of running your next study with Avance Clinical contact us: enquiries@avancecro.comAbout Avance ClinicalAvance Clinical is the largest premium full-service Australian and US CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. https://www.avancecro.com/Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past three years, has been providing CRO services in the region for more than 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.Media Contact: Avance ClinicalKate Thompsonmedia@avancecro.com Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More

Preferred Partners Announces Latest Executive Appointment

September 8, 2022
Taipei, Taiwan, September 08, 2022 – (SEAPRWire) – Preferred Partners the Taiwan based international brokerage firm has today announced the appointment of Samuel Lee as the vice president of new partnership acquisitions and development of partnerships at their Taiwan office, effective the 12th of September 2022.“Mr.Lee’s years of contributions to the success of Preferred Partners have not gone unnoticed. While working in the new partnership division for the last decade, Samuel has been an integral part of the team, bringing new profitable ideas to the company.” Luca Miller said in the conference call ” For the final month of this financial quarter, Samuel will be mainly focused on settling in to his new role, and starting from the 4th quarter he will be working closely with his team to outline a solid plan for 2023 and onwards.”The latest executive appointment for the company arose from Preferred Partners continuing campaign to increase its presence as a leader in international investments and innovative portfolio management solutions. With a continued push to partner with companies around the globe, Preferred Partners aims to increase their networking to better serve their internationally diverse client base, and bring a new wave of clients to make use of their excellent services.Preferred Partners has been offering international portfolio management services to their clients since 2002. The company specializes in short and long term investment strategies using their knowledge and market experience to bring the best results to their clients.As a highly experienced team from traditional finance and investment management, Preferred Partners understand the importance of risk controls and safeguarding client assets. Preferred Partners specialize in the US Capital Markets and have averaged a 27.5% annual return for their clients over the past 20 years.For additional information on Preferred Partners, please visit their website at: www.preferred-partners.comMedia Contact Brand: Preferred Partners Contact: Jacob Weng Email: j.weng@preferred-partners.com Website: https://www.preferred-partners.com/ SOURCE: Preferred Partners The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
OctaFX celebrates 11 years in the financial markets ACN Newswire

OctaFX celebrates 11 years in the financial markets

August 3, 2022
KUALA LUMPUR, Aug 3, 2022 - (ACN Newswire via SEAPRWire.com) - OctaFX is celebrating its 11th anniversary! Here's what the broker achieved over the years and the core elements of the brand philosophy that helped it along the way. The global broker OctaFX is bigger than ever before - all thanks to the support of its clients. Below are the main achievements OctaFX has managed to accomplish over the past eleven years.Those above are the numbers. But what is behind them? OctaFX shares the core elements of its philosophy and how they help the broker make the investment journeys of its clients as smooth as possible.OctaFX is always online. The broker has already processed 8.8 million requests and dedicated approximately 96,800,000 minutes to resolving issues and answering the questions of its clients honestly and openly.OctaFX is always looking for ways to improve, and therefore analyses all feedback carefully. Identifying the problems traders face when using its services or functionality they wish the broker had is what guides OctaFX's development. Apart from other significant changes, it managed to decrease the average verification process to around three minutes, with 85% of clients passing it on the first time.Constant change in the financial world is what keeps OctaFX agile and ready to transform and develop at all times. This approach resulted in releasing its own mobile trading and copytrading apps, adding a variety of popular financial instruments ranging from cryptocurrencies to stock indices, and developing a copytrading platform with unique features for finding and copying professional traders.Data is what OctaFX is driven by. The broker is constantly conducting research and analysis of itself, learning about the latest financial technologies - all to make sure it provides the clients not only with the best trading conditions, but also with the cutting edge technical solutions.OctaFX is focused on the goals of its clients, and that is why it tries to eliminate all the obstacles limiting their trading experience and keeping them from realising the full potential of their diverse approaches. To help its clients boost their trading and allow for a more effective use of long-term strategies, the broker decided to remove swaps entirely this May.To become yet closer to its clients, OctaFX decided to rebrand and adopt a fresh new look: with refined colours, space-inspired elements, and a new logo."All our achievements and transformations would be meaningless without our clients. It is our clients who drive our growth and allow us to always move forward. It is our clients who inspire us to be current, dynamic, innovative, confident. We thank all of them for choosing us as their broker," the OctaFX press office commented.To mark its eleventh anniversary, OctaFX has made its usually below-the-market spreads the lowest in the industry on the MT4 and MT5 platforms. The broker has reduced the spreads by 20% on XAUUSD, EURUSD, GBPUSD, USDJPY, GBPJPY, USDCHF, XTIUSD, and US30, as well as by 25% on BTCUSD and ETHUSD.About OctaFXOctaFX is a global broker providing online trading services worldwide since 2011. It offers everything one needs to reach their investment goals, providing top-notch conditions utilised already by clients from over 150 countries worldwide. The company is involved in a comprehensive network of charity and humanitarian initiatives, including improvement of educational infrastructure, short-notice relief projects, supporting local communities and small to medium enterprises. On a side note, OctaFX has also won more than 45 awards since its foundation, including the 2021 'Best Forex Broker Asia' award from Global Banking & Finance Review and 2021 'Best ECN Broker' award by World Finance. www.octafx.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More